Trial Profile
A prospective open label study to evaluate the ustekinumab for the treatment of refractory giant cell arteritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Giant cell arteritis
- Focus Therapeutic Use
- 16 Nov 2016 Long term efficacy results (n=25) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
- 08 Feb 2016 New trial record